ORTEXORTEX News
Tracking LHX? Get live short interest, options flow, and signals on ORTEX.Sign up free →
LH
Trader NoteLHX

LHX Recovers Ground Before October 29 Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 21 Oct 2026, 21:29

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

L3Harris Technologies has gained 6% this week to $248.77, a sharp reversal from the month-long drift lower that had the stock down more than 4% heading into last week, and the move lands eight days before the company reports Q3 results on October 29.

Options traders have grown noticeably more cautious even as the price has recovered. The put/call ratio rose to 0.47 on Tuesday, more than two and a half standard deviations above its 20-day average of 0.41. That is the most defensive options positioning LHX has seen relative to its recent baseline in at least a year, sitting closer to the 52-week high of 0.69 than to the low of 0.33. The pattern suggests investors are buying downside protection into the print rather than chasing the week's gains with calls. History gives them reason to be careful: the July 2026 earnings release produced an 11% one-day drop, followed by a further 6% over the following five days.

Short interest is subdued and tells a different story from the options market. At roughly 2.5% of the free float, the short position is modest and fell about 3.5% over the past week, reversing a brief rebuild noted in the prior article. Borrow conditions are extremely loose, with availability far exceeding any plausible demand for new shorts. Cost to borrow ticked up 6% on the week to 0.60%, but the absolute level remains negligible. This is not a stock where the lending market is generating signal.

The Street's direction of travel on price targets remains downward despite broadly positive ratings. RBC Capital cut its target to $265 from $310 on October 15, the most cautious call in the recent batch. Bernstein trimmed to $318 from $346 while keeping Outperform, and Goldman Sachs lowered to $361 from $405, also keeping Buy. The mean target across all analysts now sits near $317, roughly 27% above the current price. That gap has widened because the stock has fallen, not because analysts have grown more bullish: the consensus represents a corridor of maintained ratings with reduced price conviction. The PE ratio has edged up to about 18.8x over the past week as the share price recovered, and EV/EBITDA is running near 12.6x. Factor scores reflect the mixed picture: the dividend score ranks in the 93rd percentile, the days-to-cover rank in the 83rd, but analyst recommendation differential and sector scores are both near the median.

The ownership base is stable and concentrated in index and active managers. BlackRock holds roughly 10.2% and has been adding shares, reporting a net increase of more than one million shares at end-September. Wellington Management and Boston Partners have also been building positions in recent months. No 13D activists appear on the register, and all 13G filings reflect passive stakes. Recent insider activity consists entirely of routine director compensation grants at small values, not open-market purchases, and carries no meaningful signal about management's read on the stock.

What matters most in the coming week is whether the Q3 print resolves the tension between a recovering share price and a Street that has spent the past month lowering its bar. The options market has priced in caution; the short market has not.

Stocks in this article

See the live data behind this article on ORTEX.

Open LHX on ORTEX →

How this article was generated

Generated
21 Oct 2026, 21:30
Data as of
21 Oct 2026, 21:29
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.